The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter.
- Biotechnology OTC Pharmaceutical Prescription Drugs Valuation
Emerging Growth Companies
Emerging Technology Companies
Sign up for your custom alerts now, using LinkedIn ›
Back to Top